Abstract
Objective: The adjuvant therapy for high-intermediate and high-risk endometrial cancer remains controversial. A recent randomized trial (PORTEC-3) reported that survival was improved with combination chemotherapy and radiotherapy, although the survival benefit was most pronounced in women with stage III tumors. We analyzed the association between multimodal therapy and survival for women with stage I–II high- and high-intermediate risk endometrial cancer.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
